Merck & Co. (MRK) EVP Richard DeLuca sells 45,320 shares over three days

Q: What insider transaction did MRK report for Richard R. DeLuca?

Merck reported that Richard R. DeLuca , EVP & President, Merck Animal Health, sold 45,320 shares of Merck common stock in open-market or private transactions on August 10–12, 2026 , at weighted-average prices between $130.0000 and $132.6514 per share.

Q: Over what dates did the MRK insider stock sales occur?

The reported MRK insider sales by Richard R. DeLuca occurred on August 10, 11, and 12, 2026 . Each day included one or more open-market or private sale transactions in Merck common stock, with prices disclosed as weighted averages within specified ranges.

Q: How many Merck (MRK) shares did Richard R. DeLuca sell in total?

45,320 shares of Merck common stock were sold in total by Richard R. DeLuca . This figure comes from five reported non-derivative sale transactions, all coded “S” and classified as open-market or private transactions in Merck common stock.

Q: At what prices were the MRK insider sales by DeLuca executed?

The reported per-share prices are weighted averages . For the five transactions, they range from $130.4345 to $132.3496 , with underlying trade price ranges from $130.0000 up to $132.6514 , as described in the accompanying footnotes.

Q: Were Richard R. DeLuca’s MRK stock sales under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox was not selected, indicating these reported sales were not affirmatively designated as executed under a Rule 10b5-1 trading plan. No separate footnote describing such a plan appears in the provided data.

Q: What kind of transactions were reported for MRK common stock?

All reported entries are non-derivative transactions in Merck common stock with code “S” , described as sales in open market or private transactions . No option exercises or derivative security transactions are included in the provided summary data.

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

Merck & Co., Inc. executive Richard R. DeLuca, EVP & President, Merck Animal Health, reported selling a total of 45,320 shares of Merck common stock in open-market or private transactions on August 10–12, 2026weighted averages based on multiple trades within price ranges from $130.0000 to $132.6514, as detailed in footnotes. The Rule 10b5‑1 trading-plan checkbox was not selected.

Positive

None.

Negative

None.

Insights

Analyzing...

Insider Trade Summary

Net Seller: 45,320 shares

Net Sell 5 txns

Insider DeLuca Richard R.

Role EVP&Pres, Merck Animal Heallth

Sold 45,320 shs ($5.94M)

Type Security Shares Price Value

Sale Common Stock ^F4 11,099 $131.6128 $1.46M

Sale Common Stock ^F5 600 $132.0367 $79K

Sale Common Stock ^F2 7,410 $131.3313 $973K

Sale Common Stock ^F3 5,427 $132.3496 $718K

Sale Common Stock ^F1 20,784 $130.4345 $2.71M

Holdings After Transaction: Common Stock — 110,167.07 shares (Direct)

Footnotes (5)

F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.0000 to $130.9500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.9800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.0000 to $132.6514, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.9950, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.0000 to $132.0700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

Key Figures

Total shares sold: 45,320 shares Sale on 2026-08-10: 20,784 shares at $130.4345 Sale on 2026-08-11: 7,410 shares at $131.3313 +3 more

6 metrics

Total shares sold 45,320 shares Aggregate non-derivative sales of Merck common stock by Richard R. DeLuca

Sale on 2026-08-10 20,784 shares at $130.4345 Non-derivative sale; price is a weighted average with trades from $130.0000 to $130.9500

Sale on 2026-08-11 7,410 shares at $131.3313 Weighted-average price with trades from $131.0000 to $131.9800

Additional sale on 2026-08-11 5,427 shares at $132.3496 Weighted-average price with trades from $132.0000 to $132.6514

Sale on 2026-08-12 11,099 shares at $131.6128 Weighted-average price with trades from $131.0000 to $131.9950

Additional sale on 2026-08-12 600 shares at $132.0367 Weighted-average price with trades from $132.0000 to $132.0700

Key Terms

weighted average price, open market or private transaction, Rule 10b5-1, non-derivative

4 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction"

Rule 10b5-1 regulatory

"The filing’s Rule 10b5-1 checkbox was not selected"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

non-derivative financial

"transaction_type: non-derivative"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 04:11 PM Accepted by SEC EDGAR 08/12/2026 - 04:10 PM Learn about SEC filing dates

FAQ

What insider transaction did MRK report for Richard R. DeLuca?

Merck reported that Richard R. DeLuca, EVP & President, Merck Animal Health, sold 45,320 shares of Merck common stock in open-market or private transactions on August 10–12, 2026, at weighted-average prices between $130.0000 and $132.6514 per share.

Over what dates did the MRK insider stock sales occur?

The reported MRK insider sales by Richard R. DeLuca occurred on August 10, 11, and 12, 2026. Each day included one or more open-market or private sale transactions in Merck common stock, with prices disclosed as weighted averages within specified ranges.

How many Merck (MRK) shares did Richard R. DeLuca sell in total?

45,320 shares of Merck common stock were sold in total by Richard R. DeLuca. This figure comes from five reported non-derivative sale transactions, all coded “S” and classified as open-market or private transactions in Merck common stock.

At what prices were the MRK insider sales by DeLuca executed?

The reported per-share prices are weighted averages. For the five transactions, they range from $130.4345 to $132.3496, with underlying trade price ranges from $130.0000 up to $132.6514, as described in the accompanying footnotes.

Were Richard R. DeLuca’s MRK stock sales under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox was not selected, indicating these reported sales were not affirmatively designated as executed under a Rule 10b5-1 trading plan. No separate footnote describing such a plan appears in the provided data.

What kind of transactions were reported for MRK common stock?

All reported entries are non-derivative transactions in Merck common stock with code “S”, described as sales in open market or private transactions. No option exercises or derivative security transactions are included in the provided summary data.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person^*
DeLuca Richard R.
(Last) (First) (Middle)
MERCK & CO., INC.
126 EAST LINCOLN AVENUE
(Street)
RAHWAY NEW JERSEY 07065
(City) (State) (Zip)
UNITED STATES
(Country) 2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ] 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP&Pres, Merck Animal Heallth
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/10/2026 S 20,784 D $130.4345⁽¹⁾ 134,703.07 D
Common Stock 08/11/2026 S 7,410 D $131.3313⁽²⁾ 127,293.07 D
Common Stock 08/11/2026 S 5,427 D $132.3496⁽³⁾ 121,866.07 D
Common Stock 08/12/2026 S 11,099 D $131.6128⁽⁴⁾ 110,767.07 D
Common Stock 08/12/2026 S 600 D $132.0367⁽⁵⁾ 110,167.07 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.0000 to $130.9500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.9800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.0000 to $132.6514, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.9950, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.0000 to $132.0700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
/s/ Kelly E. W. Grez as Attorney-in-Fact for Richard R. DeLuca, Jr. 08/12/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Type	Security	Shares	Price	Value
Sale	Common Stock ^F4	11,099	$131.6128	$1.46M
Sale	Common Stock ^F5	600	$132.0367	$79K
Sale	Common Stock ^F2	7,410	$131.3313	$973K
Sale	Common Stock ^F3	5,427	$132.3496	$718K
Sale	Common Stock ^F1	20,784	$130.4345	$2.71M

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/10/2026		S		20,784	D	$130.4345⁽¹⁾	134,703.07	D
Common Stock	08/11/2026		S		7,410	D	$131.3313⁽²⁾	127,293.07	D
Common Stock	08/11/2026		S		5,427	D	$132.3496⁽³⁾	121,866.07	D
Common Stock	08/12/2026		S		11,099	D	$131.6128⁽⁴⁾	110,767.07	D
Common Stock	08/12/2026		S		600	D	$132.0367⁽⁵⁾	110,167.07	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

	/s/ Kelly E. W. Grez as Attorney-in-Fact for Richard R. DeLuca, Jr.	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)